The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of DISC-0974 in Participants With Myelofibrosis and Anemia
Official Title: A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis and Anemia
Study ID: NCT05320198
Brief Summary: This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Washington University St.Louis, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Sargon Research - Pennsylvania Cancer Specialists and Research Center, Gettysburg, Pennsylvania, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
MD Anderson, Houston, Texas, United States
University of Washington, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Name: Will Savage, MD PhD
Affiliation: Disc Medicine
Role: STUDY_DIRECTOR